Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It works by mimicking the satiety hormone amylin, helping to reduce appetite and food intake. It is being studied both as a standalone therapy and in combination with semaglutide (CagriSema).

Clinical trials have used weekly subcutaneous doses starting at 0.25 mg with gradual escalation to 2.4 mg over several weeks. The calculator helps determine injection volumes based on your vial concentration and reconstitution.

Cagrilintide is an amylin analogue while semaglutide is a GLP-1 receptor agonist. They target different pathways — amylin acts primarily on the area postrema in the brainstem to reduce appetite, while GLP-1 affects multiple metabolic pathways.